Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (Nasdaq: MNKD) generates frequent news across product, clinical, regulatory, and corporate fronts as it advances therapies for cardiometabolic and orphan lung diseases. News coverage for MNKD often centers on its commercial products Afrezza, FUROSCIX, V-Go, and Tyvaso DPI–related collaborations, as well as updates on its inhaled and subcutaneous pipeline.
Investors and healthcare observers following MNKD news can expect announcements on U.S. Food and Drug Administration (FDA) milestones, including supplemental Biologics License Applications and supplemental New Drug Applications. Recent examples include FDA acceptance for review of an sBLA for Afrezza in children and adolescents with type 1 or type 2 diabetes, and acceptance of an sNDA for the FUROSCIX ReadyFlow Autoinjector for edema in adults with chronic heart failure or chronic kidney disease.
MannKind’s news flow also covers clinical trial progress and portfolio decisions in orphan lung diseases. The company has reported on initiation of nintedanib DPI (MNKD-201) studies for idiopathic pulmonary fibrosis, as well as the discontinuation of the Phase 3 ICoN-1 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease following a futility analysis. Updates on pre-clinical programs such as bumetanide DPI and MNKD-102 are also featured in its communications.
Corporate and financial news items include quarterly earnings results, revenue breakdowns across royalties, collaborations, and product sales, and strategic transactions. A notable example is MannKind’s acquisition of scPharmaceuticals, which brought FUROSCIX fully into its portfolio and expanded its presence in cardiometabolic care. The company also issues releases about investor conference presentations and community initiatives, such as the Centennial Al Mann Scholarship for students living with diabetes.
This news page aggregates these developments so readers can review regulatory decisions, trial outcomes, business combinations, and financial updates related to MannKind in one place.
MannKind Corporation (MNKD) has scheduled its Q1 2025 financial results announcement for May 8, 2025, before market open. The company will host a webcast at 9:00 a.m. Eastern Time featuring CEO Michael Castagna and CFO Chris Prentiss to discuss the quarterly results and provide a business update. The webcast will be available through MannKind's investor relations website, with a replay accessible for approximately 90 days following the call.
MannKind (MNKD) has announced a continued partnership with Juncos Hollinger Racing (JHR) driver Conor Daly for the 2025 NTT INDYCAR Series season. Daly, the only known U.S. pro racing driver competing full-time with type 1 diabetes, will showcase a striking 'Tired of Pricks?' livery at the Acura Grand Prix of Long Beach on April 13.
MannKind will serve as primary sponsor for the No. 76 Chevrolet at three major events: Long Beach Grand Prix, Detroit Grand Prix (June 1), and World Wide Technology Raceway (June 15). The company will maintain an associate sponsorship throughout the 2025 season. The partnership aims to raise awareness about diabetes and innovative treatment options through InhaleMyInsulin.com.
Daly's impressive racing career includes notable achievements such as his career-best 6th place finish at the 2022 Indy 500, leading the most laps at the 2021 Indy 500, and securing JHR's first IndyCar podium at Milwaukee in 2024.
MannKind (MNKD) will present five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam, March 19-22, 2025. The presentations will showcase data from the INHALE-1 pediatric and INHALE-3 adult studies of Afrezza®.
Key presentations include research on pulmonary inhaled insulin, pediatric applications, sustained benefits from the INHALE-3 extension study, post-prandial glucose excursion comparisons between youth and adults with Type 1 diabetes, and a comparison study of inhaled Technosphere insulin plus insulin degludec versus usual care in adults.
The company anticipates filing a supplemental New Drug Application (sNDA) for Afrezza in the pediatric population in 2025. MannKind will also host booth #40 in the exhibit hall for scientific exchange with their Clinical Education Team.
MannKind (MNKD) reported strong financial results for Q4 and full year 2024. The company achieved annual revenues of $286M, up 43% from 2023, with Q4 revenues of $77M (+31% YoY). Net income for 2024 reached $28M, with Q4 contributing $7M.
Key financial highlights include debt principal reduction of $236M, with remaining convertible debt of $36M, and year-end cash position of $203M. The company made significant clinical progress, including positive results from the INHALE-1 pediatric trial for Afrezza, advancement of MNKD-101 to Global Phase 3, and completion of MNKD-201 Phase 1.
Commercial developments include Afrezza's approval in India with expected shipments in Q4 2025, and the appointment of Dominic Marasco as President of the Endocrine Business Unit. The company maintains a strong growth trajectory with an annual run rate of $300M by year-end.
MannKind (MNKD) has announced it will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. The company will host a webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.
The conference call will feature CEO Michael Castagna and CFO Chris Prentiss. Investors can access the webcast through MannKind's website, and a replay will be available for approximately 90 days following the call.
MannKind (Nasdaq: MNKD), specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in three major investor conferences during Q1 2025. The company's leadership, including CEO Michael Castagna and CFO Chris Prentiss, will present at:
- Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) - February 11, 11:20 a.m. ET
- Leerink Partners 2025 Global Healthcare Conference in Miami - March 11, 8:40 a.m. ET
- Barclays 27th Annual Global Healthcare Conference in Miami - March 12, 1:30 p.m. ET
Live audio webcasts will be accessible through MannKind's investor relations website, with recordings available for approximately 90 days post-conference.
MannKind (MNKD) has appointed Dominic Marasco, RPh, as President of its Endocrine Business Unit, effective January 6, 2025. Marasco, who brings over 25 years of experience in biopharma and biotech sectors, will report to CEO Michael Castagna.
Marasco's most recent role was Executive President and Chief Commercial Officer at Envision Pharma Group, where he led technology and AI business units. His prior experience includes leadership positions at BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals, and Eli Lilly. He holds a degree from the Philadelphia College of Pharmacy and completed Harvard Business School's Advanced Management Program.
The appointment aims to leverage Marasco's global experience to build upon Afrezza's positive clinical trial results and drive strategic growth in the company's endocrine business.
MannKind (MNKD) has announced significant debt restructuring through exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2026. The company will exchange approximately $193.7 million of Notes for 26,749,559 shares of common stock and make a cash payment of $89.2 million to the holders.
This transaction reduces MannKind's total outstanding debt by 84%, decreasing from $230 million to approximately $36.3 million. The exchange will save approximately 10.4 million shares of potential dilution and reduce annual interest expense by $4.9 million to $0.9 million. Following the exchange, MannKind's cash balance will exceed $180 million with approximately 302.5 million shares outstanding.
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17 years. The 26-week trial involved 230 subjects randomized to either Afrezza or multiple daily injections (MDI) of rapid-acting insulin.
The modified intent-to-treat (mITT) analysis, excluding one non-adherent patient, demonstrated non-inferiority of Afrezza to MDI with a between-group difference of 0.370% in HbA1c change, meeting the primary endpoint's threshold of 0.4%. No significant differences in lung function or safety parameters were observed between groups. The company plans to meet with FDA regarding a potential supplemental new drug application (sNDA) submission in first half of 2025.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
